Hydromorphone Hydrochloride | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Hydromorphone Hydrochloride
US Patents

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Hydromorphone Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

20 API Suppliers, 11 USDMF, 7 CEP/COS, 1 JDMF, 2 KDMF, 23 NDC API, 9 Listed Suppliers, $ API Reference Price

20 API Suppliers
11 USDMF
7 CEP/COS
1 JDMF
2 KDMF
23 NDC API
9 Listed Suppliers
$ API Reference Price

FINISHED DOSAGE FORMULATIONS

218 FDF Dossiers, 75 FDA Orange Book, 36 Europe, 42 Canada, 40 Australia, 5 South Africa, 20 Listed Dossiers

218 FDF Dossiers
75 FDA Orange Book
36 Europe
42 Canada
40 Australia
5 South Africa
20 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - 0.2MG/ML, INJECTABLE;INJECTION - 0.5MG/0.5ML, INJECTABLE;INJECTION - 10MG/ML, INJECTABLE;INJECTION - 1MG/ML, INJECTABLE;INJECTION - 2MG/ML, INJECTABLE;INJECTION - 4MG/ML, SOLUTION;ORAL - 5MG/5ML, TABLET;ORAL - 2MG, TABLET;ORAL - 4MG, TABLET;ORAL - 8MG, TABLET, EXTENDED RELEASE;ORAL - 12MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 16MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 32MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 0.2MG/ML
INJECTABLE;INJECTION - 0.5MG/0.5ML
INJECTABLE;INJECTION - 10MG/ML
INJECTABLE;INJECTION - 1MG/ML
INJECTABLE;INJECTION - 2MG/ML
INJECTABLE;INJECTION - 4MG/ML
SOLUTION;ORAL - 5MG/5ML
TABLET;ORAL - 2MG
TABLET;ORAL - 4MG
TABLET;ORAL - 8MG
TABLET, EXTENDED RELEASE;ORAL - 12MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 16MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 32MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Evonik, 2 Rochem International Inc, 14 SPI Pharma, 2 Seqens, 4 DKSH, 1 Jai Radhe Sales, 4 Faran Shimi Pharmaceutical, 6 Boai NKY Pharmaceuticals Ltd, 11 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 ACG Worldwide, 11 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 26 BASF, 1 Clariant, 12 Corel Pharma Chem, 6 DFE Pharma, 2 Finar, 11 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 7 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 39 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 17 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 4 Novo Excipients, 3 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 24 Roquette, 12 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 2 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

90 Fillers, Diluents & Binders, 56 Coating Systems & Additives, 41 Direct Compression, 36 Controlled & Modified Release, 29 Film Formers & Plasticizers, 28 Solubilizers, 27 Parenteral, 26 Thickeners and Stabilizers, 24 Granulation, 21 Co-Processed Excipients, 19 Lubricants & Glidants, 18 Disintegrants & Superdisintegrants, 18 Taste Masking, 18 Topical, 13 Chewable & Orodispersible Aids, 8 API Stability Enhancers, 8 Emulsifying Agents, 5 Empty Capsules, 5 Coloring Agents, 4 Rheology Modifiers, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 1 Soft Gelatin

90 Fillers, Diluents & Binders
56 Coating Systems & Additives
41 Direct Compression
36 Controlled & Modified Release
29 Film Formers & Plasticizers
28 Solubilizers
27 Parenteral
26 Thickeners and Stabilizers
24 Granulation
21 Co-Processed Excipients
19 Lubricants & Glidants
18 Disintegrants & Superdisintegrants
18 Taste Masking
18 Topical
13 Chewable & Orodispersible Aids
8 API Stability Enhancers
8 Emulsifying Agents
5 Empty Capsules
5 Coloring Agents
4 Rheology Modifiers
4 Vegetarian Capsules
4 Surfactant & Foaming Agents
1 Soft Gelatin

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 57 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
57 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 46 Finished Drug Prices

2 US Medicaid Prescriptions
46 Finished Drug Prices

MARKET PLACE

1 APIs, 2 FDF Dossiers

1 APIs
2 FDF Dossiers

PATENTS & EXCLUSIVITIES

14 US Patents, 2 US Exclusivities, 12 Health Canada Patents

14 US Patents
2 US Exclusivities
12 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 3 USP, 5 Others

2 EDQM
3 USP
5 Others

$ API Ref.Price (USD/KG) : 7,574 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

14 All

01 14FRESENIUS KABI USA

filter Patent Number Reset all filters

14 All

01 79248229

02 79731082

filter API Patent Reset all filters

14 All

01 14Blank

filter FDF Patent Reset all filters

14 All

01 14Y

filter Expiration Date Reset all filters

14 All

01 72032-04-23

02 72034-03-12

Product Main Page

01

FRESENIUS KABI USA

HYDROMORPHONE HYDROCHLORIDE

BioFlorida Conference

Not Confirmed

FRESENIUS KABI USA

BioFlorida Conference

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-03-12

HYDROMORPHONE HYDROCHLORIDE

US Patent Number : 9248229

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 19034

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-03-12

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

FRESENIUS KABI USA

HYDROMORPHONE HYDROCHLORIDE

BioFlorida Conference

Not Confirmed

FRESENIUS KABI USA

BioFlorida Conference

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-03-12

HYDROMORPHONE HYDROCHLORIDE

US Patent Number : 9248229

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 19034

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-03-12

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

FRESENIUS KABI USA

HYDROMORPHONE HYDROCHLORIDE

BioFlorida Conference

Not Confirmed

FRESENIUS KABI USA

BioFlorida Conference

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-04-23

HYDROMORPHONE HYDROCHLORIDE

US Patent Number : 9731082

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 19034

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-04-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

FRESENIUS KABI USA

HYDROMORPHONE HYDROCHLORIDE

BioFlorida Conference

Not Confirmed

FRESENIUS KABI USA

BioFlorida Conference

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-03-12

HYDROMORPHONE HYDROCHLORIDE

US Patent Number : 9248229

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 19034

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-03-12

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

FRESENIUS KABI USA

HYDROMORPHONE HYDROCHLORIDE

BioFlorida Conference

Not Confirmed

FRESENIUS KABI USA

BioFlorida Conference

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-04-23

HYDROMORPHONE HYDROCHLORIDE

US Patent Number : 9731082

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 19034

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-04-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

FRESENIUS KABI USA

HYDROMORPHONE HYDROCHLORIDE

BioFlorida Conference

Not Confirmed

FRESENIUS KABI USA

BioFlorida Conference

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-04-23

HYDROMORPHONE HYDROCHLORIDE

US Patent Number : 9731082

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 19034

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-04-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

FRESENIUS KABI USA

HYDROMORPHONE HYDROCHLORIDE

BioFlorida Conference

Not Confirmed

FRESENIUS KABI USA

BioFlorida Conference

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-03-12

HYDROMORPHONE HYDROCHLORIDE

US Patent Number : 9248229

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 19034

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-03-12

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

FRESENIUS KABI USA

HYDROMORPHONE HYDROCHLORIDE

BioFlorida Conference

Not Confirmed

FRESENIUS KABI USA

BioFlorida Conference

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-03-12

HYDROMORPHONE HYDROCHLORIDE

US Patent Number : 9248229

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 19034

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-03-12

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

FRESENIUS KABI USA

HYDROMORPHONE HYDROCHLORIDE

BioFlorida Conference

Not Confirmed

FRESENIUS KABI USA

BioFlorida Conference

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-03-12

HYDROMORPHONE HYDROCHLORIDE

US Patent Number : 9248229

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 19034

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-03-12

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

FRESENIUS KABI USA

HYDROMORPHONE HYDROCHLORIDE

BioFlorida Conference

Not Confirmed

FRESENIUS KABI USA

BioFlorida Conference

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-04-23

HYDROMORPHONE HYDROCHLORIDE

US Patent Number : 9731082

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 19034

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-04-23

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?